Identification of Key Enzalutamide-resistance-related Genes in Castration-resistant Prostate Cancer and Verification of Functions

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2023 May 30

PMID 37251536

Authors

Wen Xu

Li Liu

Zhongqi Cui

Mingyang Li

Jinliang Ni

Nan Huang

Yue Zhang

Jie Luo

Limei Sun

Fenyong Sun

Affiliations

Soon will be listed here.

Abstract

Patients with castration-resistant prostate cancer (CRPC) often develop drug resistance after treatment with enzalutamide. The goal of our study was to identify the key genes related to enzalutamide resistance in CRPC and to provide new gene targets for future research on improving the efficacy of enzalutamide. Differential expression genes (DEGs) associated with enzalutamide were obtained from the GSE151083 and GSE150807 datasets. We used R software, the DAVID database, protein-protein interaction networks, the Cytoscape program, and Gene Set Cancer Analysis for data analysis. The effect of knockdown on prostate cancer (PCa) cell lines was demonstrated using Cell Counting Kit-8, clone formation, and transwell migration experiments. Six hub genes with prognostic values were screened (, , , , , and ), which were significantly associated with immune cell infiltration in PCa. High , , , and expression was associated with androgen receptor signaling pathway activation. Except for , high expression of hub genes showed a significant negative correlation with the IC50 of Navitoclax and NPK76-II-72-1. knockdown inhibited the proliferation and migration of PC3 and DU145 cell lines and promoted apoptosis. Additionally, 22Rv1 cell proliferation was more significantly inhibited with knockdown than without knockdown under enzalutamide treatment. Overall, six key genes associated with enzalutamide resistance were screened (, , , , and ), which are potential therapeutic targets for enzalutamide-resistant PCa in the future.

References

Liu S, Gu L, Wu N, Song J, Yan J, Yang S . Overexpression of DTL enhances cell motility and promotes tumor metastasis in cervical adenocarcinoma by inducing RAC1-JNK-FOXO1 axis. Cell Death Dis. 2021; 12(10):929. PMC: 8505428. DOI: 10.1038/s41419-021-04179-5. View

Su W, Chen Y, Lai W, Lin C, Yan J, Su W . Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer. 2010; 71(1):28-33. DOI: 10.1016/j.lungcan.2010.04.009. View

Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y . Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2020; 178(2):239-261. DOI: 10.1111/bph.15300. View

Cheung W, Chu A, Chu P, Ip N . Cloning and expression of a novel nuclear matrix-associated protein that is regulated during the retinoic acid-induced neuronal differentiation. J Biol Chem. 2001; 276(20):17083-91. DOI: 10.1074/jbc.M010802200. View

Ruan Y, Xu H, Ji X, Zhao J . BLM interaction with EZH2 regulates MDM2 expression and is a poor prognostic biomarker for prostate cancer. Am J Cancer Res. 2021; 11(4):1347-1368. PMC: 8085859. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Tall A, Yvan-Charvet L . Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015; 15(2):104-16. PMC: 4669071. DOI: 10.1038/nri3793. View

Lin S, Chou F, Li L, Lin C, Yeh S, Chang C . Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Lett. 2017; 398:62-69. DOI: 10.1016/j.canlet.2017.03.035. View

Pilling A, Hwang C . Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Prostate. 2019; 79(11):1347-1359. PMC: 6617752. DOI: 10.1002/pros.23843. View

10.

Hoshi S, Meguro S, Imai H, Matsuoka Y, Yoshida Y, Onagi A . Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. Cancer Sci. 2021; 112(5):1899-1910. PMC: 8088914. DOI: 10.1111/cas.14865. View

11.

Alshareeda A, Negm O, Aleskandarany M, Green A, Nolan C, TigHhe P . Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Res Treat. 2016; 159(1):41-53. DOI: 10.1007/s10549-016-3915-8. View

12.

Tran C, Ouk S, Clegg N, Chen Y, Watson P, Arora V . Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928):787-90. PMC: 2981508. DOI: 10.1126/science.1168175. View

13.

Madan R, Karzai F, Donahue R, Al-Harthy M, Bilusic M, Rosner I . Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. J Immunother Cancer. 2021; 9(3). PMC: 7934713. DOI: 10.1136/jitc-2020-001556. View

14.

Mahley R . Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl). 2016; 94(7):739-46. PMC: 4921111. DOI: 10.1007/s00109-016-1427-y. View

15.

Siddiqui W, Ahad A, Ahsan H . The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol. 2015; 89(3):289-317. DOI: 10.1007/s00204-014-1448-7. View

16.

Davis I, Martin A, Stockler M, Begbie S, Chi K, Chowdhury S . Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019; 381(2):121-131. DOI: 10.1056/NEJMoa1903835. View

17.

Lee H, Ou C, Huang Y, Hou P, Creighton C, Lin Y . YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene. 2021; 40(13):2407-2421. PMC: 8016667. DOI: 10.1038/s41388-021-01718-4. View

18.

Luo Y, He Z, Liu W, Zhou F, Liu T, Wang G . DTL Is a Prognostic Biomarker and Promotes Bladder Cancer Progression through Regulating the AKT/mTOR axis. Oxid Med Cell Longev. 2022; 2022:3369858. PMC: 8799954. DOI: 10.1155/2022/3369858. View

19.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U . Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378(26):2465-2474. PMC: 8288034. DOI: 10.1056/NEJMoa1800536. View

20.

Sakashita K, Tanaka F, Zhang X, Mimori K, Kamohara Y, Inoue H . Clinical significance of ApoE expression in human gastric cancer. Oncol Rep. 2008; 20(6):1313-9. View